Published Paper Details:

Drug therapy may become even more complex due to the influence of genetic variability on the pharmacodynamics and/or pharmacokinetics of the psychiatric drug. DDIs that are pharmacokinetically mediated include those that are mediated by transport proteins and cytochrome P450 (CYP) enzymes. Every one of these regulatory proteins' functions in drug pharmacokinetics is examined, along with how genetically determined variations in their functional activity might change how a drug accumulates in the body. Psychotropic medication prescriptions have increased in recent years due to the growing number of individuals seeking treatment for various psychiatric diseases in primary care settings. The increasing use of psychotropic drugs is accompanied by notable disparities in the prescribing practices of primary care physicians and psychiatrists. Prescription procedures that involve the simultaneous administration of many psychiatric medications have increased the likelihood of drug-drug interactions. Adverse drug responses (ADRs) in hospitals and the general population are known to be significantly influenced by drug interactions. ADR reduction is essential to ensuring hospitalized patients take their medications safely. Evidence suggests that even mild ADRs can significantly impact psychiatric patients due to strong relationships between drug- drug interactions, treatment failures, and higher healthcare costs due to avoidable medical complications.